Filter Results:
(243)
Show Results For
- All HBS Web
(631)
- Faculty Publications (243)
Show Results For
- All HBS Web
(631)
- Faculty Publications (243)
- April 2018
- Supplement
Celgene
By: Malcolm Baker and Emily R. McComb
In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details
- March 2018
- Case
Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company
By: Rosabeth Moss Kanter and Jonathan Cohen
As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This case follows her career at the company and describes the challenges she faced as a change agent,... View Details
Keywords: Digital; Engagement; Stakeholder Engagement; Grassroots Movement; Organization Change And Adaptation; Quality; Health Care; Health Care Industry; Career Path; Leading Change; Management; Innovation and Management; Personal Development and Career; Organizational Change and Adaptation; Biotechnology Industry; Biotechnology Industry
Kanter, Rosabeth Moss, and Jonathan Cohen. "Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company." Harvard Business School Case 318-082, March 2018.
- March 2018 (Revised May 2018)
- Case
Celgene
By: Malcolm Baker and Emily McComb
In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry
Baker, Malcolm, and Emily McComb. "Celgene." Harvard Business School Case 218-094, March 2018. (Revised May 2018.)
- March 2018 (Revised May 2018)
- Supplement
Celgene (B)
By: Malcolm Baker and Emily McComb
Supplements the (A) case. View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry
Baker, Malcolm, and Emily McComb. "Celgene (B)." Harvard Business School Supplement 218-099, March 2018. (Revised May 2018.)
- January 2018
- Supplement
BeiGene Supplemental PowerPoint
By: Willy C. Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details
- January 2018
- Teaching Note
BeiGene
By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033. View Details
- November 2017
- Case
Passion and Strategy: Novozymes' Embrace of the UN Sustainable Development Goals
By: Andy Zelleke and Emilie Billaud
This case explores the sustainability efforts at Novozymes, the world's largest and oldest producer of industrial enzymes. In 2015, the Danish company became the world’s first company known to have crafted a new corporate strategy based on the United Nations... View Details
Keywords: Corporate Governance; Transformation; Environmental Sustainability; Corporate Social Responsibility and Impact; Mission and Purpose; Business and Shareholder Relations; Business and Stakeholder Relations; Business Strategy; Organizational Culture; Organizational Change and Adaptation; Biotechnology Industry; Europe; Denmark
Zelleke, Andy, and Emilie Billaud. "Passion and Strategy: Novozymes' Embrace of the UN Sustainable Development Goals." Harvard Business School Case 318-088, November 2017.
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details
Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- November 2016
- Supplement
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
By: Vicki Sato, Willy Shih and Matt Higgins
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details
Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States
Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.
- November 2016
- Case
Anthony Starks at InSiL Therapeutics (A)
By: Gary Pisano and Vicki Sato
When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a few months in, Wayne and Starks begin to clash over crucial forward-looking decisions about the... View Details
Keywords: Biotech; Silicon; Managing Innovation; Management Challenges; Managing People; Managing Organization; R&D; R&D Project Management; Platform; Venture Capital; Drug Discovery; management; Biotechnology Industry; California
Pisano, Gary, and Vicki Sato. "Anthony Starks at InSiL Therapeutics (A)." Harvard Business School Case 617-029, November 2016.
- November 2016 (Revised December 2016)
- Supplement
Anthony Starks at InSiL Therapeutics (B)
By: Vicki Sato and Gary Pisano
This case accompanies the (A) case from Anthony Starks's perspective. View Details
Keywords: Biotech; Management Challenges; R&D; R&D Project Management; Management; Biotechnology Industry; California
Sato, Vicki, and Gary Pisano. "Anthony Starks at InSiL Therapeutics (B)." Harvard Business School Supplement 617-030, November 2016. (Revised December 2016.)
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
- October 2016 (Revised September 2017)
- Case
The CRISPR-Cas9 Quarrel
By: Richard G. Hamermesh and Matthew G. Preble
In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to... View Details
Keywords: CRISPR; Broad Institute; University Of California Berkeley; Intellectual Property; Patents; Law; Lawsuits and Litigation; Science; Genetics; Entrepreneurship; Biotechnology Industry; United States
Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Case 817-020, October 2016. (Revised September 2017.)
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
- May 25, 2016
- Comment
How Consumers and Businesses are Reshaping Public Health
By: John A. Quelch
Healthcare and education are two issues in which citizens around the world, rich and poor, are passionately interested. It has long been appreciated that the way that a society treats its youngest and oldest members says much about its moral maturity. Economic... View Details
Keywords: Healthcare; Consumer Power; Innovation In Healthcare Delivery; Mobile Healthcare; Transition; Transformation; Trends; Customer Satisfaction; Customer Value and Value Chain; Health Care and Treatment; Information; Collaborative Innovation and Invention; Independent Innovation and Invention; Innovation and Management; Innovation Leadership; Management; Marketing; Markets; Planning; Problems and Challenges; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; South America; North and Central America; Middle East; Europe; Asia
Quelch, John A. "How Consumers and Businesses are Reshaping Public Health." Harvard Business School Working Knowledge (May 25, 2016).
- May 20, 2016
- Comment
World Health Organization Lacks Leadership to Combat Pandemics
By: John A. Quelch
When it comes to emergency preparedness for pandemics, the World Health Organization is falling short. It has not provided prompt and clear leadership to the world in combating either the Ebola or Zika viruses. Its leadership has been low energy, its representatives... View Details
Keywords: Global Health; World Health Organization; World Bank; Pandemics; Emergency Preparedness; Experience and Expertise; Decisions; Forecasting and Prediction; Communication Strategy; Nonverbal Communication; Framework; Governance; Government and Politics; Health; Management; Practice; Problems and Challenges; Projects; Risk and Uncertainty; Human Needs; Civil Society or Community; Social Issues; Welfare or Wellbeing; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Africa; Asia; Europe; Latin America; North and Central America; South America; West Indies
Quelch, John A. "World Health Organization Lacks Leadership to Combat Pandemics." Harvard Business School Working Knowledge (May 20, 2016).
- March 2016
- Article
Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms
By: Adam Tatarynowicz, Maxim Sytch and Ranjay Gulati
This study investigates the origins of variation in the structures of interorganizational networks across industries. We combine empirical analyses of existing interorganizational networks in six industries with an agent-based simulation model of network emergence.... View Details
Keywords: Interorganizatonal Relationships; Social Networks; Network Emergence; Interorganizational Networks; Information Technology; Networks; Organizational Structure; Social and Collaborative Networks; Social Media
Tatarynowicz, Adam, Maxim Sytch, and Ranjay Gulati. "Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms." Administrative Science Quarterly 61, no. 1 (March 2016): 52–86.
- January 2016 (Revised February 2016)
- Course Overview Note
The Sustainable Core: Operations Management
By: Michael W. Toffel and L. Beril Toktay
This note is designed to help faculty embed environmental sustainability content into their core Operations Management course at the MBA or undergraduate level. It can also be used to identify cases with environmental content that can be used in operations electives... View Details
Keywords: Environmental Management; Operations Management; Sustainable Operations; Environmental Regulation; Operations; Supply Chain; Supply Chain Management; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Toffel, Michael W., and L. Beril Toktay. "The Sustainable Core: Operations Management." Harvard Business School Course Overview Note 616-022, January 2016. (Revised February 2016.)
- 2016
- Book
Consumers, Corporations, and Public Health: A Case-Based Approach to Sustainable Business
By: John A. Quelch
The public health footprint associated with corporate behavior has come under increased scrutiny in the last decade, with an increased expectation that private profit not come at the expense of consumer welfare.
Consumers, Corporations, and Public... View Details
Consumers, Corporations, and Public... View Details
Keywords: Consumer; Corporate Culture; Public Health; Consumer Behavior; Marketing Strategy; Corporate Strategy; Health; Innovation and Invention; Innovation and Management; Supply Chain Management; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Asia; Oceania; North and Central America; Middle East; Latin America; Europe
Quelch, John A. Consumers, Corporations, and Public Health: A Case-Based Approach to Sustainable Business. New York: Oxford University Press, 2016.
- Article
What to Know About Locating in a Cluster
By: Willy C. Shih and Sen Chai
As a study of two industry clusters in Denmark shows, factors that can make clusters attractive—easy people movement and knowledge spillovers—can also make it harder for individual companies to retain proprietary knowledge. View Details
Keywords: Clusters; Clustering; Competitiveness; Life Sciences; Telecommunications; Science-based; Research And Development; Industry Clusters; Research; Innovation Strategy; Innovation and Management; Geographic Location; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Denmark
Shih, Willy C., and Sen Chai. "What to Know About Locating in a Cluster." Art. 57117. MIT Sloan Management Review 57, no. 1 (Fall 2015): 104–107.